Editorial Board
Dr. Gross received a masters (M.S.) in Biology from the California State University and his doctorate (Ph.D.) in Cell Biology from the University of California, Los Angeles. He did his postdoctoral training at Tulane University School of Medicine. He has also done postgraduate programs at the Wharton School, Harvard/Tufts Law Schools and MIT. Dr. Gross is also faculty in the Jefferson College of Biomedical Sciences and the Sydney Kimmel Medical College of Thomas Jefferson University, Professor of Experimental Therapeutics and Medicinal Chemistry in the Blumberg Institute and Adjunct Professor of Basic Sciences at The Commonwealth Medical College. He has published more than 120 scientific publications. He currently is also the CEO of the Pennsylvania Drug Discovery Institute.
Dr. Beyer is President & CEO of Promentis Pharmaceuticals, Inc. He has nearly 20 years of experience in the research, discovery and business development of medications aimed to treat CNS and neurological disorders. Previously, Dr. Beyer served as the Head of Neurochemistry at Wyeth Pharmaceuticals in Princeton, NJ. During his career at Wyeth, Dr. Beyer holds a Ph.D. in Neuropharmacology from LSU Medical Center and an MBA from the Rutgers Business School. Notably, Dr. Beyer has authored more than 70 manuscripts, 3 patents, and co-edited "Next Generation Antidepressants." Dr. Beyer is also an adjunct faculty member at Thomas Jefferson University in Philadelphia where he teaches "Bioventure Management", a class focused on the business of doing science.
Dr. Reitz obtained a doctorate (Ph.D.) in Chemistry from the University of California, San Diego. Dr. Reitz also holds an Executive Masters in Technology Management from the University of Pennsylvania (Wharton, Penn Engineering).
Currently Dr. Reitz is also an Adjunct Professor in the Drexel University College of Medicine. He has published more than 150 scientific publications and is a named inventor of 60 issued U.S patents.
Dr. Reitz was the founding Editor (2000) and is currently the Editor-in-Chief of this
journal (
Dr. Steinman holds a doctorate in biomedical sciences from the University of Massachusetts Medical School and an MBA from the university’s Isenberg School of Management. She graduated Summa Cum Laude from Baldwin-Wallace College with dual degrees in biology and psychology in the honors program.
Heather Steinman, Ph.D., MBA, is Vice President for Business Development and Executive Director of Technology Transfer at The Wistar Institute, the nation’s first independent research institution devoted solely to biomedical science and a world leader in cancer, immunology, virology and infectious disease research.
Dr. Steinman brings more than 18 years of experience in technology transfer and commercialization of early stage-life science discoveries.
Dr. Moira Gunn is an Associate Professor at University of San Francisco. She did her MS in Computer Science and PhD in Mechanical Engineering from Purdue University, Lafayette, IN, USA. Dr. Gunn has been teaching courses at the University of San Francisco since 1979. She was the Director of Information Systems Program in USF from 2007 to 2009. She is the leader of Business of Biotechnology Program in USF School of Management. She received Educator of the Year award from EE Times in 2008. She has also received Public Service Award for contribution to the public understanding of science and engineering from National Science Board in 2011.
Dr. Xielin LIU is a professor in School of Economics and Management, Director of Research Center for Innovation and Entrepreneurship, University of Chinese Academy of Sciences. He was a research fellow in Chinese Academy of Science and Technology for Development, Ministry of Science and Technology(1996-2006) and professor in Tsinghua University from 1985-2006. His research areas mainly cover innovation management and policy, innovation ecosystem, regional and national innovation system. He has published a lot of papers in Research Policy, Technovation, Journal of Management Studies and International Journal of Technology Management, Science and Public Policy. He served as editor for Research Policy and other journals. He has published many books in English: Regional Innovation Index of China:2017(2018, Springer), Environmental Innovation in China(WIT,2012) and Innovation, Technology Policy and Regional Development with Tim Turpin (Edward Elgar, 2003).
Dr. Garrison earned his Ph.D. in Biological Sciences - Neuroscience from the University of Wisconsin, Milwaukee (USA) before completing his postdoctoral training in sensory biology at the Medical College of Wisconsin, Milwaukee (USA). He has previously worked with successful start-up companies in drug development, biotech consulting and bioinformatics. Currently, Dr. Garrison serves as a Research Scientist for the Aurora Research Institute, Aurora Health Care, and is the Wisconsin State Leader for the National Organization for Rare Disorders (NORD).
Dr Berenstein is Advisor to Vicepresident from CONICET and independent consultant in Technology transfer and Biobusiness for Scientific Community, Industry and Investment groups.With more than 20 years of experience both in Research and technology transfer, she also held Management level positions in both public institutions and private companies in the Life Science Industry. She was previously Vice Director, General Manager, and Director of leading Offices of Technology transfer and Bio-incubators in Argentina (CONICET and Instituto Leloir).Dr Berenstein holds a PhD in Gene therapy from University of Buenos Aires and an MBA from University of San Andrés. She is also Academic Director and Professor of Postgraduates courses in Pharma and Biotechnology business from leading business Universities in Argentina.
Dr. Asit K. Chakraborti is Professor and Head of the Department of Medicinal Chemistry, NIPER, S. A. S. Nagar, Punjab, India. He received Ph. D. degree in Synthetic Organic Chemistry from the Indian Association for the Cultivation of Science (IACS), Kolkata, India. He has published 166 research papers (with > 7600 citation and h index of 51) and filed 42 patents. He received several awards and recognition such as University Gold Medal, Bardhaman Sammilani Gold Medal, ISMAS Eminent Mass-spectroscopist Award, etc. He is the Fellow of the Royal Society of Chemistry and Indian Science Academies.
Dr. Cullis is the Francis Hobart Herrick Professor of Biology at Case Western Reserve University and Director of the Biotechnology Entrepreneurship Master’s Program. He is currently President of the Society for Bioentrepreneurship Education and Research (SIBER). His research has focused primarily on rapid genomic variation in plants. He is also currently working on developing a wild legume (marama, Tylosema esculentum) into a crop for resource poor farmers in Southern Africa. He has served as a program director at the National Science Foundation, on grant review panels, advisory and on editorial advisory boards of multiple journals.
Karl Dakin has 38 years in innovation commercialization. Mr. Dakin is a respected educator, extraordinary communicator, visionary leader with an entrepreneurial spirit and a small business advocate. Mr. Dakin is engaged in multiple new product, business and economic development projects. At the crossroads of capital and food, he is leading the development of a new democratized capital ecosystem within the State of Colorado where everyone can invest in Main Street businesses and he is increasing local food production by development, sale and operation of turnkey indoor agriculture systems.
Nina Ossanna, PhD holds a PhD in Molecular Biology and is a registered US patent agent. She is a founder and VP Business Development for Pharos Diagnostics and owner of Sonora Bioconsulting. She also Chairs the Bioindustry Organization of Southern Arizona. She has worked in university tech transfer directing offices at Johns Hopkins Medical School and the University of Arizona as well as working in start-up life science companies.
Dr. Ozsolak is an Associate Director at Vertex Pharmaceuticals. He previously worked at Biogen and RaNA Therapeutics, contributing to the discovery and development of drugs to treat CNS, liver and kidney diseases via small molecule and oligotherapeutics approaches. He obtained his PhD in biological chemistry and molecular pharmacology from Harvard University, and BA in biochemistry from Washington University in St. Louis.
Frederick J. Schoen, M.D., Ph.D., is Professor of Pathology and Health Sciences and Technology (HST) at Harvard Medical School, and Executive Vice-Chairman of the Department of Pathology at Brigham and Women's Hospital (BWH). His research focuses on native and substitute heart valves. In institutional roles, he promotes multidisciplinary innovation using technology, provides mentoring and career development leadership for translational research, and teaches Pathology, Biomaterials, Tissue Engineering and Medical Device Development. He serves on the Massachusetts Life Sciences Center SAB, and many academic and governmental advisory, grant review and editorial committees, and consults with medical device companies.
Dr. Tezlaff did her B.A. from University of Wisconsin-Milwaukee, Milwaukee, WI, USA; Ph.D. from Loyola University Chicago, Maywood, IL, USA; and Postdoctorate from Massachusetts General Hospital of the Harvard Medical School, Boston, MA, USA. She worked as a scientist at Seaside Therapeutics, Cambridge, MA from 2008 till 2011. In 2011, she joined Department of Pathology of the Medical College of Wisconsin and has been working there as an Assistant Professor since then. She has also been serving as the Assistant Dean of Postdoctoral Education at the Medical College of Wisconsin since 2014. Her research interest includes Sudden Infant Death Syndrome, Infant Mortality, Neuroscience, Biomarkers, Professional and career development and Entrepreneurial initiatives.
Dr. Tobet obtained a master’s degree (S.M.) and doctorate (Ph.D.) in Applied Biological Sciences from the Massachusetts Institute of Technology in Cambridge, MA. After 14 years in Boston as faculty at Harvard Medical School and then University of Massachusetts Medical School, he moved to Colorado State University (CSU) as a Professor in the College of Veterinary Medicine and Biomedical Sciences in 2003. In 2010 he was named the Director of the CSU School of Biomedical Engineering. He has published more than 135 papers in scientific journals. At CSU he helped create and deliver courses in Biomedical Entrepreneurship, Grant Writing, and STEM Communication.
Dr. Nagaraj R. Banapurmath is a Professor and Head for Department of Mechanical Engineering at B.V.B. College of Engineering & Technology, Hubli, Karnataka, India. He completed his Ph.D in Mechanical Engineering and M.Tech in Heat power Engineering. He has vast teaching and research experience. His research interests include Alternative fuels for internal combustion engines, Nano-composites for Structural and Energy applications. He is a reviewer for many National and International Journals. He received many awards for his professional and educational excellence and published many papers in International Journals, National and International Conferences.